Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16670482 | 0.91 | BTK (0.41) | BTKGAAEPHX2CTSKNFKB1 | |
| Hydrochloric Acid SCHEMBL30327314 | 0.90 | BTK (0.40) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL14669045 | 0.89 | BTK (0.49) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL19381847 | 0.85 | BTK (0.50) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL26969338 | 0.84 | BTK (0.42) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL21287424 | 0.84 | BTK (0.42) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL8894795 | 0.84 | BTK (0.45) | BTKGAAEPHX2CTSKNFKB1 | |
| Hydrochloric Acid SCHEMBL25282690 | 0.83 | BTK (0.44) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL13708409 | 0.82 | GAA (0.36) | BTKGAAEPHX2CTSKNFKB1 | |
| SCHEMBL31158980 | 0.81 | BTK (0.43) | BTKGAAEPHX2CTSKNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4646197-A2 | ORGANIC COMPOUNDS AS NLRP3 INHIBITORS | Kodiak Sciences Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20250084041-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | THE UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2025-03-13 | — | — | US | disclosed |
| CN-119320383-A | Nitrogen-containing heteroaryl compound, and preparation method and application thereof | 北京鞍石生物科技股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240408216-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4457217-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-10-10 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-8901145-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2699569-A2 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012145617-A9 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2014-02-20 | — | — | WO | disclosed |
| WO-2013127266-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | GENENTECH, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2012145617-A2 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120270892-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| EP-0641339-B1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5407943-A | Azaspiro quinolone antibacterial agents | PFIZER INC. (US) | 1995-04-18 | — | — | US | disclosed |
| EP-0641339-A1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1992022550-A1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | BTK 479/4885GAA 1988/4885EPHX2 4638/4885 |
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | PRMT5, PRMT1, PRMT6 | BTK 1274/4885GAA 2633/4885EPHX2 3810/4885 |
| US-20120270892-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | BTK 360/4885GAA 1098/4885EPHX2 4782/4885 |
| US-20240408216-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | PSME1, IDE, PRUNE1 | BTK 4140/4885GAA 250/4885EPHX2 1795/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | BTK 479/4885GAA 1988/4885EPHX2 4638/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | BTK 3914/4885GAA 4545/4885EPHX2 2762/4885 |
| US-20250084041-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | MPO, NISCH, RPN2 | BTK 1068/4885GAA 173/4885EPHX2 4197/4885 |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN6, PTPN2 | BTK 187/4885GAA 4098/4885EPHX2 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.